L'intérêt à découvert pour MetLife donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de MetLife. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

MetLife (NYSE:MET) Stock, Rapport sur les intérêts à découvert

MetLife

MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.

MetLife Inc

Metronome

Meta Platforms, Inc. - Class A Common Stock

Meta Platforms Inc

Metadium

MetagamZ

MetaPets

MetaverseX

META PLATFORMS CL A ORD

Ramaco Resources, Inc. - Class A Common Stock

Ramaco Resources Inc

Ramaco Resources, Inc. - Class B Common Stock

Ramaco Resources, Inc. - 9.00% Senior Notes due 2026

Direxion Daily META Bear 1X Shares

FRANKLIN METAVERSE SINGLECLASS ETF

Metis - United States Dollar

FT INDXX FUT ECON METALS UCITS ETF

ISH ESS MTL US ACC ETF

METEORIC RESORCES NL by Meteoric Resorces NL

Meteoric Resources NL

ETC GROUP WEB 3.0 UCITS ETF ACC GBX

Direxion Daily META Bull 2X Shares

Roundhill Ball Metaverse ETF

ME THERAPEUTICS HLDGS by ME THERAPEUTICS HLDGS INC.

ME Therapeutics Holding Inc

METLIFE ORD

MetLife, Inc. Preferred Series A Floating Rate

MetLife, Inc. Depositary shares, each representing a 1/1000th interest in a share of the Issuera??s 5.625% Non-Cumulative Preferred Stock, Series E.

MetLife, Inc. Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F

In the current session, the stock is trading at $85.60, after a 0.49% increase. Over the past month, MetLife Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) stock increased by 5.77%, and in the past year, by 42.66%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1729171809_0.png" alt="Past Year Chart" />

<h3>MetLife P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 18.7 in the Insurance industry, MetLife Inc. has a higher P/E ratio of 23.15. Shareholders might be inclined to think that MetLife Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729171809_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

News

Intraday Update

Markets

P/E Ratio Insights for MetLife

Wells Fargo analyst Elyse Greenspan maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Overweight and raises the price target from $86 to $92.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on MetLife, Raises Price Target to $92

TD Cowen analyst Daniel Bergman initiates coverage on MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Buy rating and announces Price Target of $97.

Initiation

TD Cowen Initiates Coverage On MetLife with Buy Rating, Announces Price Target of $97

WIIM

CRBG

GSIW

LPLA

SOFI

TIGR

Shares of companies within the broader financial sector are trading higher amid overall market strength following strong September Unemployment Rate and Nonfarm Payrolls data. Also, the dockworkers struck a deal to suspend their strike after they reached a tentative agreement, easing concerns about its potential ramifications.

Piper Sandler analyst John Barnidge maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Overweight and raises the price target from $85 to $92.

Piper Sandler Maintains Overweight on MetLife, Raises Price Target to $92

Throughout the last three months, 10 analysts have evaluated MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $88.2, a high estimate of $96.00, and a low estimate of $83.00. This upward trend is evident, with the current average reflecting a 2.56% increase from the previous average price target of $86.00.
<img src="https://www.benzinga.com/files/images/story/2024/1727467240_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive MetLife. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$91.00</td>
<td>-</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$81.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to MetLife. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MetLife compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of MetLife's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of MetLife's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MET/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MetLife analyst ratings.</a>
<h2>Delving into MetLife's Background</h2>
MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.
<h3>MetLife's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining MetLife's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.73% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: MetLife's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): MetLife's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.27%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.13%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: MetLife's debt-to-equity ratio surpasses industry norms, standing at 0.67. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From MetLife Analyst Ratings: What You Need To Know

Jefferies analyst Suneet Kamath maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Buy and raises the price target from $89 to $95.

Jefferies Maintains Buy on MetLife, Raises Price Target to $95

MetLife, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/met#NYSE">MET</a>) benefits on the back of a well-performing Group Benefits business, acquisitions and partnerships, cost-cutting efforts and strong cash balance.
<h2>Zacks Rank &amp; Price Performance</h2>
MetLife carries a Zacks Rank #2 (Buy) at present.
The stock has gained 10% in the past three months compared with the industry&#39;s growth of 5.3%. The Zacks Finance sector and the S&amp;P 500 composite index have returned 0.8% and 2.4%, respectively, in the said time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/c8/77767.jpg?v=1023352585" />
Image Source: Zacks Investment Research
<h2>Favorable Style Score</h2>
MetLife carries an impressive Value Score of A. Value Score helps find stocks that are undervalued. Back-tested results show that stocks with a Value Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2, offer the best opportunities in the value investing space.
<h2>Robust Growth Prospects</h2>
The Zacks Consensus Estimate for MetLife&#39;s 2024 earnings is pegged at $8.67 per share, which indicates an improvement of 18.3% from the 2023 reported figure. The consensus mark for revenues is $73.2 billion, implying a rise of 2% from the 2023 figure. MET&#39;s earnings estimates witnessed seven upward revisions over the past 60 days against no downward movement.
The consensus mark for 2025 earnings is pegged at $9.83 per share, suggesting an improvement of 13.4% from the 2024 estimate. The same for revenues is $76.5 billion, hinting at a 4.6% increase from the 2024 estimate.
<h2>Valuation</h2>
Price-to-book (P/B) is one of the multiples used for valuing insurance stocks. Compared with the multiline industry&#39;s trailing 12-month P/B ratio of 2.57, MetLife has a reading of 1.92. It is quite evident that the stock is currently undervalued.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/0a/77768.jpg?v=1057971813" />
Image Source: Zacks Investment Research
<h2>Solid Return on Equity</h2>
Return on equity in the trailing 12 months is currently 21.4%, which is higher than the industry&#39;s average of 16.2%. This substantiates the company&#39;s efficiency in utilizing shareholders&#39; funds.
<h2>Business Tailwinds</h2>
A key revenue contributor is MetLife&#39;s steady premiums, which have been recovering from pandemic-driven declines. Premiums are witnessing a steady increase in the Group Benefits business, wherein it rose 4% year over year in the first half of 2024. Growth has also been robust in its EMEA and Latin America segments, further contributing to the company&#39;s revenue stream.
MetLife&#39;s focus on streamlining its business, coupled with strategic acquisitions and partnerships, is expected to drive long-term growth. The company has expanded its presence in key areas like vision care and pet insurance through acquisitions, such as Versant Health and PetFirst. It has also strengthened its benefits offerings through partnerships with firms like Aura and Nayya.
A strategic push into private credit investments, marked by the acquisition of Raven Capital, and a collaboration with Fidelity Investments on a fixed immediate income annuity further diversify its business portfolio. Additionally, MetLife continues to reduce volatility by divesting capital-intensive units and intensifying focus on high-growth areas. &nbsp;
MetLife&#39;s cost-saving measures have resulted in notable operational improvements. Between 2015 and 2020, the company saw an improvement of 230 basis points in its direct expense ratio. This efficiency trend has continued, with the direct expense ratio remaining below the guided 12.3% in the first half of 2024.
MetLife also benefits from a strong liquidity position, with short-term debt of $390 million as of June 30, 2024, significantly overshadowed by its $20.8 billion in cash and cash equivalents. This financial strength underpins shareholder returns through repurchases and dividend payments. In April 2024, management approved a 4.8% dividend increase.
<h2>Other Stocks to Consider</h2>
Some other top-ranked stocks in the insurance space include CNO Financial Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cno#NYSE">CNO</a>), MGIC Investment Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mtg#NYSE">MTG</a>) and Palomar Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plmr#NASDAQ">PLMR</a>), each sporting a Zacks Rank #1 at present.
The bottom line of CNO Financial outpaced estimates in three of the trailing four quarters and missed the mark once, the average surprise being 21.21%. The Zacks Consensus Estimate for CNO&#39;s 2024 earnings suggests 11% year-over-year growth. The consensus mark for CNO Financial&#39;s 2024 earnings has moved north by 3% in the past 30 days.
MGIC Investment&#39;s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 15.59%. The Zacks Consensus Estimate for MTG&#39;s 2024 earnings indicates 9.1% year-over-year growth, while the same for revenues implies an improvement of 4.7%. MGIC Investment&#39;s consensus mark for 2024 earnings has moved north by 2.2% in the past 30 days.
The bottom line of Palomar outpaced estimates in each of the trailing four quarters, the average surprise being 17.10%. The Zacks Consensus Estimate for PLMR&#39;s 2024 earnings suggests 30.9% year-over-year growth, while the same for revenues implies an improvement of 41.6%. The consensus mark for Palomar&#39;s 2024 earnings has moved north by 1.3% in the past 30 days.
Shares of CNO Financial, MGIC Investment and Palomar have gained 24.2%, 22.4% and 18.3%, respectively, in the past three months.
<a href="https://www.zacks.com/stock/news/2336089/analyzing-metlife-stock-is-buy-strategy-the-right-move?cid=CS-BENZ-FT-analyst_blog|rank_focused-2336089">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Mid Cap

Dividends

Management

Trading Ideas

PLMR

Analyzing MetLife Stock: Is Buy Strategy the Right Move?

MetLife's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) short percent of float has risen 3.82% since its last report. The company recently reported that it has 7.94 million shares sold short, which is 1.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>MetLife Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725997522_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MetLife has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing MetLife's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, MetLife's peer group average for short interest as a percentage of float is 2.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into MetLife's Recent Short Interest

Barclays analyst Alex Scott initiates coverage on MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Overweight rating and announces Price Target of $91.

Barclays Initiates Coverage On MetLife with Overweight Rating, Announces Price Target of $91

MetLife's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) short percent of float has risen 3.82% since its last report. The company recently reported that it has 7.94 million shares sold short, which is 1.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>MetLife Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724351413_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for MetLife has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing MetLife's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, MetLife's peer group average for short interest as a percentage of float is 2.98%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into MetLife's Recent Short Interest

MetLife Appoints Jude Driscoll As President Effective Sept. 1

Morgan Stanley analyst Nigel Dally maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Overweight and lowers the price target from $86 to $85.

Morgan Stanley Maintains Overweight on MetLife, Lowers Price Target to $85

Throughout the last three months, 9 analysts have evaluated MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $86.0, a high estimate of $96.00, and a low estimate of $80.00. This upward trend is evident, with the current average reflecting a 1.31% increase from the previous average price target of $84.89.
<img src="https://www.benzinga.com/files/images/story/2024/1723496444_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of MetLife by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$96.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$83.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Kevin Heal</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to MetLife. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MetLife compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for MetLife's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MetLife's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MET/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MetLife analyst ratings.</a>
<h2>Unveiling the Story Behind MetLife</h2>
MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial services products. The company is organized into five segments: us, Asia, Latin America, EMEA, and MetLife Holdings. The U.S. business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile with the Latin America segment contributing around 13% of earnings. The EMEA and the MetLife segments contribute around 4% and 11% of earnings, respectively.
<h3>A Deep Dive into MetLife's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining MetLife's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.73% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: MetLife's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 5.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): MetLife's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.27%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): MetLife's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.13%, the company may face hurdles in achieving optimal financial returns.
Debt Management: MetLife's debt-to-equity ratio surpasses industry norms, standing at 0.67. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying MetLife: Insights From 9 Analyst Reviews

Wells Fargo analyst Elyse Greenspan maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Overweight and raises the price target from $85 to $86.

Wells Fargo Maintains Overweight on MetLife, Raises Price Target to $86

ACGL

Brighthouse Financial, Inc. - Common Stock

CINF

GOCO

OSCR

RELI

SLQT

Shares of insurance companies are trading lower amid overall weakness following concerns for recently issued US economic data.

ALLY

ARES

ENVA

HOOD

IBKR

KSPI

NCPL

NTRS

PIPR

TROW

UPST

VALU

Shares of companies within the broader financial sector are trading lower amid overall market weakness following weak US jobs data.

B of A Securities analyst Joshua Shanker maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Buy and lowers the price target from $99 to $96.

B of A Securities Maintains Buy on MetLife, Lowers Price Target to $96

MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) reported quarterly earnings of $2.28 per share which beat the analyst consensus estimate of $2.11 by 8.06 percent.

Earnings Beats

MetLife Q2 2024 Adj. EPS $2.28 Beats $2.11 Estimate

<a href="https://www.bloomberg.com/news/articles/2024-07-26/blackrock-elliott-among-thames-creditors-leading-crisis-talks?srnd=util" title="https://www.bloomberg.com/news/articles/2024-07-26/blackrock-elliott-among-thames-creditors-leading-crisis-talks?srnd=util">https://www.bloomberg.com/news/articles/2024-07-26/blackrock-elliott-among-thames-creditors-leading-crisis-talks?srnd=util</a>
&nbsp;
A group of <a href="https://www.thameswater.co.uk/">Thames Water&#39;s</a> creditors including BlackRock Inc. and Elliott Investment Management LP formed a coordination committee as talks kicked off with the struggling utility over options to restructure its debt load, according to people familiar with the matter.
The committee formed last week is part of a larger group of creditors who are being advised by investment bank Jefferies and law firm <a href="https://www.akingump.com/en/lawyers-advisors">Akin Gump</a>, said the people, who asked not to be named discussing private information. The broader group holds about &pound;8.5 billion ($10.9 billion) of Thames Water debt.

"BlackRock, Elliott Among Thames Creditors Leading Crisis Talks; Invesco, MetLife Also Are On Committee For Debt Negotiations; Committee Is A Sign That Pace Of Talks Is Likely To Pick Up" - Bloomberg News

Jefferies analyst Suneet Kamath maintained a Buy rating on Metlife (MET – Research Report) today and set a price target of $95.00. The company's sh...

Metlife (MET) Receives a Buy from Jefferies

Undercovered Dozen: Burford Capital, Metlife, Garrett Motion, Kaspi +

In a report released today, John Barnidge from Piper Sandler maintained a Buy rating on Metlife (MET – Research Report), with a price target of $92...

Piper Sandler Keeps Their Buy Rating on Metlife (MET)

As the Federal Reserve's interest rate cuts reshape the economic landscape, insurance stocks are poised for growth. With rising portfolio values and the potential for lower insurance costs, this could be an opportune time for investors to scoop up the shares of MetLife (MET), Prudential Financial (PRU), and Lincoln National Corp. (LNC) with attractive dividend yields. Read on… The insurance sector is known for generating solid long-term profits as it thrives in both flourishing and challenging economic periods. Below, I have highlighted three fundamentally sound insurance stocks, namely, MetLife, Inc. (<a href="https://stocknews.com/stock/MET/">MET</a>), Prudential Financial, Inc. (<a href="https://stocknews.com/stock/PRU/">PRU</a>), and Lincoln National Corporation (<a href="https://stocknews.com/stock/LNC/">LNC</a>). These companies offer attractive dividend yields, providing a blend of income stability and potential for capital appreciation.
The recent half-point interest rate cut by the Federal Reserve is <a href="https://insurancenewsnet.com/innarticle/insurance-experts-see-good-news-after-fed-cuts-rates-by-a-half-point">beneficial</a> for the insurance industry because it reduces borrowing costs. For life insurance companies that invest in long-term, fixed-rate securities, the value of their investments is likely to increase, even if some indexed products face short-term challenges. On the property and casualty side, the rise in portfolio values could lead to lower insurance costs in the near future.
According to <a href="https://www.statista.com/outlook/fmo/insurances/worldwide#:~:text=Looking%20ahead%2C%20the%20gross%20written%20premium%20is%20anticipated%20to%20show%20an%20annual%20growth%20rate%20of%202.38%25%20(CAGR%202024%2D2029)%2C%20resulting%20in%20a%20market%20volume%20of%20US%249.02tn%20by%202029.">Statista</a>, the global insurance market is anticipated to reach a gross written premium of $9.02 trillion by 2029, growing at a CAGR of 2.4%.
Moreover, while the rate cuts may result in higher premiums, they also encourage the adoption of advanced technologies like AI and GenAI, pushing insurers to explore these innovations to enhance their operations. As a result, AI in the insurance industry is projected to reach $35.77 billion by 2030, exhibiting a <a href="https://appinventiv.com/blog/ai-in-insurance/">CAGR of 33.1%</a>.
With that in mind, let's evaluate the fundamentals of three <a href="https://stocknews.com/category/life-insurance/">Insurance - Life</a> stocks, beginning with #3.
Stock #3: Lincoln National Corporation (<a href="https://stocknews.com/stock/LNC/">LNC</a>)
LNC and its subsidiaries operate multiple insurance and retirement businesses through four segments: Annuities; Life Insurance; Group Protection; and Retirement Plan Services. The company distributes its products through consultants, brokers, planners, agents, financial advisors, third-party administrators, and other intermediaries.
On August 22, buoyed by strong financial performance, the company declared a quarterly <a href="https://www.investopedia.com/terms/d/dividend.asp">dividend</a> of $0.45 per share, payable on November 01, to the shareholders of record on October 10, 2024.
LNC pays an annual dividend of $1.80, which translates to a yield of 5.88% at the current share price. Its four-year average dividend yield is 4.72%. Moreover, the company's dividend payouts have increased at an impressive CAGR of 4.6% over the past five years.
In the same month, LNC enhanced its Lincoln PathBuilder Income&#xAE; product by adding a lifetime income guarantee to its asset allocation fund. This upgrade, part of Lincoln's broader suite of guaranteed income solutions, offers greater flexibility and customization for plan sponsors and participants. This development will likely increase LNC's appeal in the retirement planning market and boost its revenue potential.
For the second quarter of 2024, which ended on June 30, LNC's revenue increased 75.9% year-over-year to $5.15 billion. Its net income available to common stockholders stood at $884 million, up 76.1% year-over-year, while its net income available per share amounted to $5.11, representing an increase of 73.8% from the last year.
Street expects LNC's revenue for the fiscal fourth quarter (ending December 2024) to increase 136.6% year-over-year to $4.65 billion. Moreover, its EPS estimate of $1.79 for the same period indicates a 23.6% year-over-year growth.
LNC shares have surged 26.4% over the past year and 13.5% year-to-date to close the last trading session at $30.61.
LNC's stance is apparent in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an A grade for Momentum and a B for Value. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
Among the 26 stocks in the B-rated <a href="https://stocknews.com/category/life-insurance/">Insurance - Life</a> industry, it is ranked #25. <a href="https://stocknews.com/stock/LNC/">Click here</a> to see the additional ratings for LNC (Growth, Stability, Sentiment, and Quality).
Stock #2: Prudential Financial, Inc. (<a href="https://stocknews.com/stock/PRU/">PRU</a>)
PRU provides insurance, investment management, and other financial products and services internationally. It operates through five segments: PGIM; Retirement Strategies; Group Insurance; Individual Life; and International Businesses.
On September 12, the company paid its shareholders a quarterly dividend of $1.30 per common stock. With 15 years of consecutive dividend growth, PRU pays an annual dividend of $5.20, which translates to a yield of 4.37% at the current share price. Its four-year average dividend yield is 4.84%. Moreover, its dividend payouts have increased at a CAGR of 5.7% over the past five years.
On August 20, PRU announced an agreement to reinsure a portion of its guaranteed universal life block with Wilton Re. The terms state that Wilton Re will reinsure approximately $11 billion of reserves backing Prudential's guaranteed universal life policies. This transaction advances PRU's strategic progress toward becoming a higher-growth and more capital-efficient company.
PRU's total adjusted operating income before income taxes for the second quarter (ended June 30, 2024) increased 11.1% year-over-year to $1.61 billion, while the PGIM segment reported an adjusted operating income before taxes of $206 million, indicating a 15.1% growth from the prior-year quarter. The company's attributable net income came in at $1.19 billion and $3.28 per share, up 134.4% and 137.7% year-over-year, respectively.
Analysts expect PRU's revenue for the third quarter (ended September 2024) to increase 11.9% year-over-year to $13.66 billion, while its EPS for the same period is expected to grow 1.8% from the prior year to $3.50. Moreover, it topped the consensus revenue estimates in three of the trailing four quarters, which is promising.
Over the past year, the stock has surged 27.4%, closing the last trading session at $118.95.
PRU's mixed fundamentals are reflected in its POWR Ratings. The stock has an A grade for Growth and Momentum. It is ranked #18 in the same B-rated industry. <a href="https://stocknews.com/stock/PRU/">Click here</a> to see the other PRU rating for Value, Stability, Sentiment, and Quality.
Stock #1: MetLife, Inc. (<a href="https://stocknews.com/stock/MET/">MET</a>)
MET is a financial services company that provides insurance, annuities, employee benefits, and asset management services to individual and institutional customers. It operates through six segments: Group Benefits; Retirement and Income Solutions (RIS); Asia; Latin America; Europe, the Middle East and Africa (EMEA); and MetLife Holdings.
On September 10, demonstrating its commitment to returning value to shareholders, the company paid a quarterly dividend of $0.55 per share. MET pays an annual dividend of $2.18, which translates to a yield of 2.67% at the current share price. Its four-year average dividend yield is 3.14%. Also, the company's dividend payouts have increased at a CAGR of 4.4% over the past five years.
During the second quarter that ended on June 30, 2024, MET's total revenues increased 7.2% year-over-year to $17.82 billion, while the company's adjusted premiums, fees and other revenues, excluding PRT came in at $11.77 billion, reflecting an increase of 3.6% from the prior year quarter. In addition, its adjusted earnings amounted to $1.63 billion and $2.28 per share, reflecting an increase of 9.1% and 17.5% year-over-year, respectively.
The consensus revenue estimate of $18.54 billion for the fiscal third quarter (ended September 2024) represents a 16.9% increase year-over-year. The consensus EPS estimate of $2.26 for the same quarter indicates a 14.6% improvement year-over-year. The company has an impressive earnings surprise history; it surpassed the EPS estimates in three of the trailing four quarters.
The stock has gained 32.6% over the past year and 21.4% over the past nine months to close the last trading session at $81.79.
It's no surprise that MET has an overall rating of B, equating to a Buy in our POWR Ratings system. It has an A grade for Growth and Momentum. Out of 26 stocks in the Insurance - Life industry, MET is ranked #7.
Beyond what is stated above, we've also rated MET for Value, Stability, Sentiment, and Quality. Get all MET ratings <a href="https://stocknews.com/stock/MET/">here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
MET shares were trading at $81.50 per share on Thursday morning, down $0.29 (-0.35%). Year-to-date, MET has gained 26.20%, versus a 20.57% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/met-pru-lnc-3-insurance-stocks-with-attractive-dividend-yields/>3 Insurance Stocks With Attractive Dividend Yields</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Insurance Stocks With Attractive Dividend Yields

There's a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on Metlife (MET – Research Report) and LPL Financial (LP...

Analysts Offer Insights on Financial Companies: Metlife (MET) and LPL Financial (LPLA)

MetLife declares $0.545 dividend

UBS' highest and lowest scoring 'quantamental signal' ideas

Wells Fargo analyst Elyse Greenspan maintained a Buy rating on Metlife (MET – Research Report) today and set a price target of $92.00. The company'...

Metlife (MET) Gets a Buy from Wells Fargo

Dividend Roundup: Pfizer, Caterpillar, PNC Financial, AbbVie, and more

Morgan Stanley screens for quality cyclicals as economic surprises, yields back upgrade

AAPL

ABBV

ADSK

ANET

AVGO

AVNT

AVTR

BCDRF

BURL

CAIXY

CBRE

CHTR

CIFR

CIFRW

CIXPF

DASH

EBAY

ESGR

ESGRO

ESGRP

EWBC

FANG

FTNT

GOOGL

HALO

HBAN

HSIC

HUBS

IDXX

ILMN

INTC

KNTNF

LBRDA

LBRDB

LBRDK

LBRDP

MNST

NVDA

ODFL

ORCL

PAYX

SBAC

SEDG

SOXX

SPOT

TEAM

TMUS

TRGP

TSCO

XRAY

Press Releases

MetLife Names Toby Srihiran Brown as Global Head of Reinsurance, Rob Dill as Chief Auditor

MetLife Sponsors Third Annual Toyota HBCUNY Classic Presented by Walmart at MetLife Stadium

New MetLife Survey: Women Drawn to STEM Careers in the Face of Tech Disruption, Which Could Help Bridge STEM Talent Shortage

MetLife's Upwise Helps Drive Up Benefits Enrollment, Engagement and Value

MetLife to Hold Conference Call for Third Quarter 2024 Results

AM Best Affirms Issue Credit Rating of MetLife, Inc.'s Reopened Senior Unsecured Notes

MetLife Poll Finds Growing Percentage of Plan Sponsors with De-Risking Goals Looking to Completely Divest Their Company's Pension Liabilities in the Near Future

Comments

MetLife

Intérêt court

MetLife (NYSE:MET) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL